Vontobel Holding’s Humacyte HUMA Stock Holding History

Vontobel Holding’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,000	Closed	-$50.5K	–	1117
2024 Q4	$50.5K	Buy	+10,000	New	+$49.5K	﹤0.01%	1072

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Vontobel Holding's HUMA Position: Q1 2025 in Review

Vontobel Holding sold out of Humacyte (HUMA) in Q1 2025, closing a stake of 10,000 shares — an estimated $50.5K sold.

Vontobel Holding first reported a position in HUMA in Q4 2024 and held it in 1 quarter. The position peaked at $50.5K in Q4 2024. 168 funds tracked by Wall St. Rank hold HUMA as of Q1 2025.

Vontobel Holding reported no remaining Humacyte position as of Q1 2025 after selling out during the quarter.
Vontobel Holding sold 10,000 Humacyte shares in Q1 2025, an estimated $50.5K.
Vontobel Holding first reported a position in Humacyte in Q4 2024 and held it in 1 quarter.
Vontobel Holding's Humacyte position peaked at $50.5K in Q4 2024.
168 funds tracked by Wall St. Rank held Humacyte as of Q1 2025.

Based on Vontobel Holding's 13F filing for Q1 2025, filed 28 Apr 2025.